Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years ...

Hunter Tate has received news that he is officially in remission, moving from a high-risk to a low-risk protocol and no ...

The Final Rule permits an investment adviser to exclude from its AML/CFT program advisory services provided to another investment adviser subject to the Final Rule. FinCEN explained that this ...

This Peninsula biotech company started as a way to find a cancer drug for a co-founder's father. It now layoffs show it’s ...

The community unites to host a music festival to fundraise for Dylan René, 6, and her father, Josiah Menard who are facing ...

Learn more about whether Arcellx Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on AAII's A+ Investor ...

TC BioPharm Holdings (NASDAQ: TCBP) announced on Thursday morning that the first patient has successfully completed the full dosing regimen in the ACHIEVE Phase 2b trial for TCB008, receiving all four ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...